Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech?

Alnylam shares have fallen more than 40% this year despite the company’s financials being described as strong. The article attributes investor concern to a guidance cut and a clinical setback involving a rival drug; it provides no further figures or detail on the guidance change.